Clinical Trial Update: Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of camrelizumab and apatinib in high-risk gestational trophoblastic neoplasia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gestational Trophoblastic Neoplasia

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Gestational Trophoblastic Neoplasia | Phase 2 | Status: RECRUITING